ViiV Healthcare retains #1 position for eighth year in a row in PatientView’s ‘Corporate Reputation of Pharma – from the Patient Perspective 2020 - 2021’ survey results
2020 was not a year that anyone could have predicted. It presented unique challenges across the globe, including for the HIV community and the healthcare sector. However, in the face of a global crisis, at ViiV Healthcare, never have we been clearer in our mission to ensure that no person living with HIV is left behind. We are therefore delighted to have been recognised for our continued commitment to the community during these unprecedented times and we have been ranked 1st in PatientView’s ‘Corporate Reputation of Pharma – from the Patient Perspective 2020 - 2021’ survey for the eighth year running.
ViiV Healthcare is the only pharmaceutical company solely focused on combating, preventing, and ultimately curing HIV and AIDS, but of course, none of what we do can be achieved alone – we believe in the power of partnership with the HIV community. In the last year we have been particularly proud to have launched several new initiatives in collaboration with our community partners aimed at dismantling the pervasive stigma that drives the HIV epidemic, including Tackle HIV, Being Seen and HIV in View. We also took swift action at the start of the pandemic with our COVID-19 Emergency Response Fund, which saw us grant £3 million to research and community-based projects working to help eliminate HIV-related stigma and discrimination, improve health outcomes and ensure that people living with HIV, vulnerable communities and the wider public have access to comprehensive HIV information and services.
We would like to thank the many individuals and organisations who not only work alongside us on our shared journey to make HIV a smaller part of people’s lives, but who also took the time to participate and share their views in this survey. We thank you and we value your partnership which continues to spur us forward in progressing ever closer to the UN target of ending the AIDS epidemic by 2030.
Harmony Garges, Chief Medical Officer and Stephen Rea, Head of External Affairs and Communications, ViiV Healthcare
For our corporate press office, email: Kate Senter, Director of Corporate Communications
OR call +44(0)7796 707 446
For US-specific media enquiries,email: Audrey Abernathy
OR call +1 919 605 4521
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.